HC Wainwright & Co. has reiterated its 'Buy' rating for Syndax Pharmaceuticals but reduced its price target from $38 to $36. Despite the target reduction, the new price still implies a substantial potential upside of 174.8% from the November 2, 2026 closing price, suggesting continued analyst confidence in the company's long-term prospects.
HC Wainwright & Co. reaffirmed its 'Buy' rating for Syndax Pharmaceuticals, indicating continued positive sentiment towards the company. However, the firm lowered its price target from $38 to $36, a 5.3% decrease. This adjustment suggests a slight recalibration of expectations, possibly due to market conditions, updated financial models, or recent company developments not explicitly detailed in the filing. Despite the reduction, the new price target still represents a significant potential upside of 174.8% based on the closing price of $13.10 on November 2, 2026, which could be seen as a long-term opportunity for investors. For traders, the immediate impact might be neutral to slightly negative due to the lowered target, but the reaffirmed 'Buy' rating and substantial implied upside could attract long-term investors. The key risk is whether the company can achieve the growth necessary to reach this ambitious price target.